Shield Therapeutics Share Discussion Threads

[ny boy] 03/6/2019 16:53

Shield said no date for the appeal hearing had yet been set but it believed the initial EPO decision would be upheld and would update on proceedings as required.

In a note, analysts at Shield’s ‘house’ broker Peel Hunt said appeals of this kind were “typical”; of the generics industry and the original decision and breadth of the Feraccru patent provided significant defensibility for the company’s IP.

[montyhedge] 03/6/2019 16:37

yeas
The market makers were shaking the tree and a few weak holders fell out.

[ny boy] 03/6/2019 16:17

Nobby, yes the rns made me chuckle, news we already knew or was likely to happen, some of us pickpocketed those selling lol
I’m happy, certainly wasn’t expecting to see a drop like that, shows there are savvy bargain hunters around. Quite a few that missed the early rises, managed to get a decent entry too, many are happy today.

[nobbygnome] 03/6/2019 16:03

So you have to laugh; the price is more or less back to where we started, which of course is completely logical. Badly informed investors who panic always make poor decisions. They provided the rest of us with a unique opportunity to profit from their weakness. Onwards and upwards!

[78steve] 03/6/2019 15:57

Blue finish coming up

[montyhedge] 03/6/2019 15:55

NY
275p by Christmas, if given the ok 27th July.

[ny boy] 03/6/2019 15:21

New month buying, everyone got a present this morning, a few got mugged, as has happened in each decade since the 20’s, tick tock 27 July!

[volsung] 03/6/2019 14:06

Might end up blue at this rate :)

[nobbygnome] 03/6/2019 14:03

This is about the generics market not a takeover IMHO. For me it is a compliment that Teva see Ferracru as a drug with great potential as a generic.

[ny boy] 03/6/2019 13:35

Teva are getting very worries, trying their best to keep the share price in check so they can negotiate a lower takeover deal, hopefully STX will chose a better partner, leaving Teva in a poor negotiating position and having to make a huge price offer to take control, all good for STX shareholders, onwards & upwards, loving this pull back!

[montyhedge] 03/6/2019 12:12

NY
Not long to go, Teva can't see them winning anything.

[ny boy] 03/6/2019 10:13

Well that was nice, managed to get a few more sub 100p, not easy but that was a great opp imo onwards and upwards TEVA are obviously playing the game and getting a bit hot under the collar lol

Dave, just noticed the (MSYS) news, it’s a long term hold for me, I know it will do well, holding a few million shares, last top up 1p. GL

[crankyman] 03/6/2019 10:06

Defending against patents challenges is part of competition in the market place. Having deep pockets is required. Getting a big upfront from the US deal would do that. In any case, the Company should provide more context to the current challenge. It’s left is investors hanging a bit. Just as the first CKD announcement was not properly contexted.

[nobbygnome] 03/6/2019 09:53

A few muppets got panicked into selling this morning. My understanding is that the patents being challenged are post 2030 and all the patents up until then are fine. This is what the CEO said at the Investor evening but DYOR.

[volsung] 03/6/2019 08:54

Final load up at 95.72p

[peachie 74] 03/6/2019 08:47

How sure are we about being ok until 2030 ?

[nobbygnome] 03/6/2019 08:43

I have filled my boots below a pound. Ridiculous MM inspired fall this morning. I predict a strong recovery later today.

[volsung] 03/6/2019 08:38

Bought a stash more at 100.5p

[dave4545] 03/6/2019 08:37

Strange you've not commented on the exciting MSYS new nyboy ??

[ny boy] 03/6/2019 08:31

I know, so a great opp to buy I am getting ready, well leaving a buy order in as out most of today.

[nobbygnome] 03/6/2019 08:22

This is non news this morning. This patent dispute relates to post 2030 as far as I am aware and is Teva trying to sort out the generic market ahead of the game. In a way it is a complement because Teva think this drug is worth it.

Certainly the fall this morning is not merited on this news and is definitely a buying opportunity ahead of the FDA decision.

[hashertu] 03/6/2019 08:20

Is an appeal the norm in such cases?
I suspect that, from TEVA's perspective, having done all the preparatory work for the first trial, the risk/reward favours an appeal. They can afford to take the risk, so why not?

[peachie 74] 01/6/2019 10:10

Proactive Investor videos very interesting watching.
The fact that Shield are already lining companies up in the US ready to take feraccru to market shows the level of confidence of getting FDA approval.
And the CEO almost scoffs at a 90p share price ( at the time of filming)
Exciting times.
The company providing the IV market leader ferinject ( which Feraccru has been shown to be non inferior ) has a 8.5 billion market cap. Wow. The market is huge.
A non inferior oral alternative to Ferinject really has enormous worldwide potential.
Good luck everyone

[ny boy] 31/5/2019 16:17

And again L2 3 v 1. Strange trading, MM pick pocketing a few loose investors. Looking for a add myself, got to go out, let an order lower down, just in case.